Business · 02/12/2003Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for INVANZ Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for INVANZ, a human drug product, in accordance with patent extension regulations, as a result of a submission to the US Department of Commerce's Director of Patents and Trademarks.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →